The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

作者：Susan L. Furth, Helen M. Colhoun, Mehmet Kanbay, Aleksandra Kukla, Lee‐Ling Lim, Helen MacLaughlin, Sankar D. Navaneethan, Rukshana Shroff, Peter Stenvinkel, Michael Cheung, Jennifer King, Morgan E. Grams, Michel Jadoul, Peter Rossing, Radica Z. Alicic, Urmila Anandh, Carla María Avesani, Juan Jesús Carrero, Juliana C.N. Chan, Alex R. Chang, Ricardo V. Cohen, Beatriz Fernández‐Fernández, Sharlene A. Greenwood, Mads Hornum, Thomas H. Inge, Trond Jenssen, Vivekanand Jha, Holly Kramer, Elaine Ku, Kelly Lambert, Wells W. Larsen, Adrian Liew, Jayme E. Locke, Andrea O. Y. Luk, Magdalena Madero, Johannes F. E. Mann, Enrique Morales, Jacinda M. Nicklas, Irene L. Noronha, Niels Olsen, John Ortiz, Michelle M. O’Shaughnessy, Esteban Porrini, Jorge Rico-Fontalvo, Ivan Rychlík, Naveed Sattar, Laura Solá, María José Soler, Stella Stabouli, Paul E. Stevens, Duane Sunwold, Rita S. Suri, Irma Tchokhonelidze, Matias Trillini, Yusuke Tsukamoto, Katherine R. Tuttle, Angela Yee‐Moon Wang, Mai-Szu Wu · 发表于：Kidney International · 年份：2025 · DOI：10.1016/j.kint.2025.09.019 · 被引用次数：26 · 研究领域：Diabetes Treatment and Management、Chronic Kidney Disease and Diabetes、Bariatric Surgery and Outcomes

Obesity and chronic kidney disease (CKD) are complex diseases that are interlinked directly and indirectly. In October 2024, Kidney Disease: Improving Global Outcomes (KDIGO) held a Controversies Conference on the Relationship Between Obesity and CKD: Pathophysiology, Prognosis, and Management. The goals of the conference were to examine the most recent evidence regarding the epidemiology, pathophysiology, and treatment of obesity and CKD as well as to articulate priorities for research. A key conference theme was increasing the awareness of obesity-related CKD. Long-term, early-onset obesity and prolonged exposure to obesity carry the highest risk of developing CKD. Identifying early biomarkers of kidney dysfunction and refining assessment methods in the context of obesity could provide opportunities for preventing loss of kidney function. The foundation for managing obesity in CKD comprises modifications to diet, physical activity level, and behaviors related to both. However, these strategies can be unsuccessful in achieving or maintaining weight loss for a myriad of reasons. Pharmacotherapies, such as those including glucagon-like peptide-1 receptor agonists, are effective in weight reduction and have been shown to have kidney-protective and cardiovascular benefits. Metabolic and bariatric surgery has also demonstrated benefits in reducing obesity-related complications. Appropriateness and choice of management strategies will vary depending on age and comorbidities and ma...